Browsing: Diabetes Mellitus

PICO

Ebenatide (PEGylated Exenatide) Improves Glycemic Control, Time in Range, and Body Composition in Type 2 Diabetes

By FWAJuly 4, 20250

Clinical Context The GLP-1 receptor agonist (GLP-1 RA) class has expanded dramatically, with agents differentiated by dosing frequency (daily vs.…

PICO

Circulating Gremlin 2 Decreases With Worsening Glucose Tolerance and Correlates With Beta-Cell Function

By FWAApril 25, 20250

Clinical Context Type 2 diabetes ultimately results from beta-cell failure—the inability of pancreatic beta cells to produce sufficient insulin to…

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

CONTACT INFO

Privacy Policy
Disclaimer

Browsing: Diabetes Mellitus

Ebenatide (PEGylated Exenatide) Improves Glycemic Control, Time in Range, and Body Composition in Type 2 Diabetes

Circulating Gremlin 2 Decreases With Worsening Glucose Tolerance and Correlates With Beta-Cell Function

Once-Weekly Semaglutide Shows Promise in Improving Glycaemic Control and Weight Loss for Type 2 Diabetes Patients, Study Finds

Study Finds Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes Patients, but Raises Retinopathy Concerns

Study Shows Once-Weekly Semaglutide Effectively Lowers Blood Sugar and Aids Weight Loss in Type 2 Diabetes Patients

Once-Weekly Semaglutide Outperforms Daily Sitagliptin in Blood Sugar and Weight Control for Type 2 Diabetes Patients

Subscribe now

CATEGORIES

CONTACT INFO